Prevention du diabete de type 2: un nouveau defi de sante publique.

Diabetes Mellitus, Type 1/genetics/physiopathology/prevention & control; Diet; Exercise; Genetic Predisposition to Disease; Humans; Obesity/complications; Public Health; Risk Factors; Weight Loss

Abstract :

[en] Owing to the epidemics of type 2 diabetes, it is important to develop strategies of prevention of the disease. The first step should detect patients at risk, in function of simple anamnesis, clinical and biological criteria. Afterwards, those individuals should be encouraged to follow a prevention programme, which essentially comprises better lifestyle habits (diet and physical exercise), especially to prevent or correct weight excess. In at very high risk subjects, for instance because of moderately increased fasting or post-glucose load glucose levels, eventually in a context of family history of type 2 diabetes, a pharmacological approach could be considered. Various drugs (metformin, acarbose, glitazones, orlistat, inhibitors of the renin-angiotensin system) have proven their efficacy in reducing the incidence of type 2 diabetes, in particular in individuals with impaired glucose tolerance, with obesity and/or with arterial hypertension.

Disciplines :

Endocrinology, metabolism & nutrition

Author, co-author :

Scheen, André ; Université de Liège - ULiège > Département des sciences cliniques > Diabétologie, nutrition et maladie métaboliques - Médecine interne générale

Giet, Didier ; Université de Liège - ULiège > IFRES - Médecine générale

Language :

French

Title :

Prevention du diabete de type 2: un nouveau defi de sante publique.

Alternative titles :

[en] Prevention of type 2 diabetes: a new public health challenge

Publication date :

2005

Journal title :

Revue Médicale de Liège

ISSN :

0370-629X

eISSN :

2566-1566

Publisher :

Université de Liège. Revue Médicale de Liège, Liège, Belgium

Special issue title :

Le diabète sucré dans tous ses états

Volume :

Issue :

5-6

Pages :

383-90

Peer reviewed :

Peer reviewed

Additional URL :

http://www.rmlg.ulg.ac.be

Available on ORBi :

since 08 April 2009

Statistics

Number of views

2391 (9 by ULiège)

Number of downloads

2538 (6 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

Bibliography

Lefèbvre PJ.- Le diabète hier, aujourd'hui et demain. L'action de la Fédération Internationale du Diabète. Rev Med Liège, 2005, 60, 273-277.
WHO Study Group.- Prevention of diabetes mellitus: report of WHO study group. WHO Tech Rep Ser, 1994, 844, 1-100.
American Diabetes Association and National Institute of Diabetes, Digestive and Kidney Diseases.- The prevention or delay of type 2 diabetes. Diabetes Care, 2002, 25, 742-749.
Schulze MB, Hu FB.- Primary prevention of diabetes: what can be done and how much can be prevented? Annu Rev Public Health, 2005, 26, 445-467.
Scheen AJ, Paquot N, Jandrain B.- Comment j'explore... le risque d'un patient d'évoluer vers un diabète de type 2. Rev Med Liège, 2002, 57, 113-115.
Scheen AJ, Letiexhe MR, Ernest Ph.- Prévention du diabète de type 2: style de vie ou médicaments? Rev Med Liège, 2003, 58, 206-210.
Scheen AJ, Van Gaal LF, Brohet C, et al.- Belgian Evaluation of Screening and Treatment of high risk patients based on waist and age (BEST): focus on diabetes mellitus and metabolic syndrome (Abstract). Diabetes, 2005, 54 (Suppl), in press.
Scheen AJ.- Prevention of type 2 diabetes mellitus through inhibition of the renin-angiotensin system. Drugs, 2004, 64, 2537-2565.
Luyckx FH, Castillo MJ.- Apport de la biologie clinique dans la mise au point et le suivi d'un patient diabétique. Rev Med Liège, 2005, 60, 590-593.
de Veght F, Dekker JM, Jager A, et al.- Relation of impaired fasting and postload glucose with incident type 2 diabetes in a Dutch population: The Hoorn Study. JAMA, 2001, 285, 2109-2113.
Lorenzo C, Okoloise M, Williams K, et al.- The metabolic syndrome as predictor of type 2 diabetes. Diabetes Care, 2003, 26, 3153-3159.
Scheen AJ, Van Gaal LF.- Le diabète de type 2 au coeur du syndrome métabolique: plaidoyer pour une prise en charge globale. Rev Med Liège, 2005, 60, 566-571.
American Diabetes Association. Position Statement.- Evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes and related complications. Diabetes Care, 2003, 26 (Suppl 1), S51-61.
Padwal R, Majumdar SR, Johnson JA, et al.- A systematic review of drug therapy to delay or prevent type 2 diabetes. Diabetes Care, 2005, 28, 736-744.
Freemark M.- Pharmacologic approaches to the prevention of type 2 diabetes in high risk pediatric patients. J Clin Endocrinol Metab, 2003, 88, 3-13.
Rorive M, Letiexhe MR, Scheen AJ, Ziegler O.- Obésité et diabète de type 2. Rev Med Liège, 2005, 60, 374-382.
Paquot N.- Le régime alimentaire chez le patient diabétique de type 2. Rev Med Liège, 2005, 60, 391-394.
Tuomilehto J, Lindström J, Ericksson JG, et al for the Finnish Diabetes Prevention Study Group.- Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. New Engl J Med, 2001, 344, 1343-1350.
Diabetes Prevention Program Research Group.- Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med, 2002, 346, 393-403.
Magis D, Geronooz I, Scheen AJ.- Tabagisme, insulinorésistance et diabète de type 2. Rev Med Liège, 2002, 57, 575-581.
Magis D, Jandrain BJ, Scheen AJ.- Alcool, sensibilité à l'insuline et diabète sucré. Rev Med Liège, 2003, 58, 501-507.
Koppes LLJ, Dekker JM, Hendriks HFJ, et al.- Moderate alcohol consumption lowers the risk of type 2 diabetes. A meta-analysis of prospective observational studies. Diabetes Care, 2005, 28, 719-725.
Salazar-Martinez E, Willett WC, Ascherio A, et al.- Coffee consumption and risk for type 2 diabetes mellitus. Ann Intern Med, 2004, 140, 1-8.
Tuomilehto J, Hu G, Bidel S, et al.- Coffee consumption and risk of type 2 diabetes mellitus among middle-aged Finnish men and women. JAMA, 2004, 291, 1213-1219.
Chiasson J-L, Josse RG, Gomis R, et al for the STOP-NIDDM Trial Research Group.- Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet, 2002, 359, 2072-2077.
Scheen AJ.- Is there a role for α-glucosidase inhibitors in the prevention of type 2 diabetes mellitus? Drugs, 2003, 63, 933-951.
Buchanan TA, Xiang AH, Peters RK, et al.- Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk Hispanic women. Diabetes, 2002, 51, 2796-2803.
Keating GM, Jarvis B.- Orlistat. In the prevention and treatment of type 2 diabetes mellitus. Drugs, 2001, 61, 2107-2119.
Scheen AJ, Ernest Ph.- Antiobesity treatment in type 2 diabetes: results of clinical trials with orlistat and sibutramine. Diab Metab, 2002, 28, 437-445.
Torgerson JS, Hauptman J, Boldrin MN, Sjöström L.- Xenical in the Prevention of Diabetes in Obese Subjects (XENDOS) study. A randomised study of orlistat as an adjunct to lifestyle for the prevention of type 2 diabetes in obese patients. Diabetes Care, 2004, 27, 155-161.
Van Gaal LF, Pfeiffer FW- The importance of obesity in diabetes and its treatment with sibutramine. Int J Obes Relat Metab Disord, 2001, 25 (Suppl 4), S24-28.
Van Gaal LF, Rissanen AM, Scheen AJ, et al.- Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet, 2005, 365, 1389-1397.
Scheen AJ.- Prévention de l'apparition du diabète de type 2 par l'inhibition du système rénine-angiotensine. Rev Med Liège, 2002, 57, 449-452.
Scheen AJ.- Réduction comparable des nouveaux cas de diabète de type 2 sous sartan et sous inhibiteurs de l'enzyme de conversion de l'angiotensine: comparaison des méta-analyses des essais prospectifs randomisés. Rev Med Liège, 2005, 60, 424-428.
Wallemacq C, Van Gaal LF, Scheen AJ.- Le coût du diabète de type 2: résumé de l'enquête européen ne CODE-2 et analyse de la situation en Belgique. Rev Med Liège, 2005, 60, 278-284.
Scheen AJ.- Preventing, delaying or masking type 2 diabetes with metformin in the Diabetes Prevention Program? (Letter). Diabetes Care, 2003, 26, 2701.